Analysts’ Weekly Ratings Updates for Voyager Therapeutics (VYGR)

Several brokerages have updated their recommendations and price targets on shares of Voyager Therapeutics (NASDAQ: VYGR) in the last few weeks:

  • 2/9/2019 – Voyager Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
  • 2/4/2019 – Voyager Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 2/2/2019 – Voyager Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
  • 1/30/2019 – Voyager Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $9.00 price target on the stock. According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
  • 1/26/2019 – Voyager Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. They now have a $9.25 price target on the stock. According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
  • 1/19/2019 – Voyager Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $9.50 price target on the stock. According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
  • 1/15/2019 – Voyager Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock. They wrote, “Our $21 price target is based on a 13-year DCF analysis leveraged solely to the prospects of VY- AADC in PD, which potentially leaves significant upside if the remainder of the pipeline matures favorably. Our DCF analysis is based on: beta of 1.47, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027.””
  • 1/10/2019 – Voyager Therapeutics had its “neutral” rating reaffirmed by analysts at Chardan Capital.
  • 1/8/2019 – Voyager Therapeutics had its price target lowered by analysts at BTIG Research to $23.00. They now have a “positive” rating on the stock.

VYGR traded down $0.17 during trading hours on Monday, hitting $10.55. 153,905 shares of the company’s stock were exchanged, compared to its average volume of 534,543. Voyager Therapeutics Inc has a 12-month low of $7.76 and a 12-month high of $31.91. The company has a market cap of $349.60 million, a P/E ratio of -4.00 and a beta of 2.58.

Institutional investors and hedge funds have recently made changes to their positions in the stock. AlphaCrest Capital Management LLC purchased a new position in shares of Voyager Therapeutics in the 4th quarter valued at $102,000. Bank of New York Mellon Corp grew its position in shares of Voyager Therapeutics by 4.2% in the 4th quarter. Bank of New York Mellon Corp now owns 88,459 shares of the company’s stock valued at $831,000 after buying an additional 3,543 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in shares of Voyager Therapeutics by 66.8% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,380 shares of the company’s stock valued at $101,000 after buying an additional 4,559 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Voyager Therapeutics in the 4th quarter valued at $433,000. Finally, Virtus ETF Advisers LLC grew its position in shares of Voyager Therapeutics by 33.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 29,207 shares of the company’s stock valued at $275,000 after buying an additional 7,338 shares during the last quarter. 88.47% of the stock is currently owned by hedge funds and other institutional investors.



Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Featured Article: Asset Allocation

Receive News & Ratings for Voyager Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply